Validation Data Gallery
Filter:
Tested Applications
| Positive WB detected in | HeLa cells, mouse lung tissue, SH-SY5Y cells |
| Positive IHC detected in | human colon tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | U2OS cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 4 publications below |
| IHC | See 6 publications below |
Product Information
18098-1-AP targets B3GNT3 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | B3GNT3 fusion protein Ag12061 相同性解析による交差性が予測される生物種 |
| Full Name | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 |
| Calculated molecular weight | 372 aa, 43 kDa |
| Observed molecular weight | 43 kDa |
| GenBank accession number | BC066876 |
| Gene Symbol | B3GNT3 |
| Gene ID (NCBI) | 10331 |
| RRID | AB_10596928 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9Y2A9 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Beta-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3) is a type II transmembrane protein located in the Golgi apparatus and contributes to the regulation of L-selectin ligand function, lymphocyte trafficking, and T cell homing. B3GNT3 is overexpressed in breast cancer, and also plays a critical role in the aggressiveness of pancreatic cancer (PMID: 33718036, 30466404). Western blot analysis detected B3GNT3 at an apparent molecular mass of 43 kDa.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for B3GNT3 antibody 18098-1-AP | Download protocol |
| IHC protocol for B3GNT3 antibody 18098-1-AP | Download protocol |
| IF protocol for B3GNT3 antibody 18098-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Cancer Cell Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. | ||
Transl Lung Cancer Res Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. | ||
PLoS One B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer. | ||
BMC Bioinformatics A novel glycosylation-related gene signature predicts survival in patients with lung adenocarcinoma | ||
J Clin Pathol B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer. | ||
Oncol Lett B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma. |